Revolution Medicines (RVMD) Expected to Announce Earnings on Wednesday

Revolution Medicines (NASDAQ:RVMD) is anticipated to post its Q4 2025 results after the market closes on Wednesday, February 25th. Analysts expect the company to announce earnings of ($1.56) per share and revenue of $3.8940 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, February 25, 2026 at 4:30 PM ET.

Revolution Medicines Stock Up 1.8%

RVMD stock opened at $103.69 on Tuesday. The company has a market cap of $20.05 billion, a price-to-earnings ratio of -20.06 and a beta of 1.00. The company has a fifty day moving average price of $97.12 and a 200 day moving average price of $68.93. The company has a debt-to-equity ratio of 0.16, a current ratio of 8.05 and a quick ratio of 8.05. Revolution Medicines has a 12 month low of $29.17 and a 12 month high of $124.49.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on RVMD shares. Needham & Company LLC upped their target price on shares of Revolution Medicines from $66.00 to $72.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Wedbush reaffirmed an “outperform” rating on shares of Revolution Medicines in a research note on Friday, January 9th. Benchmark reaffirmed an “overweight” rating on shares of Revolution Medicines in a research report on Tuesday, February 17th. UBS Group upgraded Revolution Medicines to a “strong-buy” rating in a research note on Thursday, December 4th. Finally, Royal Bank Of Canada initiated coverage on Revolution Medicines in a research note on Monday, November 3rd. They set an “outperform” rating and a $77.00 price target for the company. Four research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Revolution Medicines presently has a consensus rating of “Buy” and an average target price of $78.94.

Insiders Place Their Bets

In other Revolution Medicines news, insider Mark A. Goldsmith sold 15,394 shares of the stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $76.82, for a total value of $1,182,567.08. Following the completion of the transaction, the insider owned 232,469 shares in the company, valued at approximately $17,858,268.58. This represents a 6.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Jack Anders sold 10,000 shares of the firm’s stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $98.00, for a total value of $980,000.00. Following the completion of the sale, the chief financial officer directly owned 108,065 shares of the company’s stock, valued at approximately $10,590,370. This trade represents a 8.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 113,792 shares of company stock worth $10,734,640. Company insiders own 8.20% of the company’s stock.

Institutional Trading of Revolution Medicines

Institutional investors have recently added to or reduced their stakes in the stock. Nextech Invest Ltd. increased its stake in shares of Revolution Medicines by 20.7% during the 4th quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock worth $332,472,000 after purchasing an additional 1,304,347 shares in the last quarter. Millennium Management LLC grew its holdings in Revolution Medicines by 681.8% during the 1st quarter. Millennium Management LLC now owns 156,353 shares of the company’s stock valued at $5,529,000 after buying an additional 136,353 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Revolution Medicines by 14.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 300,196 shares of the company’s stock worth $10,615,000 after buying an additional 37,345 shares in the last quarter. Invesco Ltd. raised its holdings in shares of Revolution Medicines by 19.3% in the second quarter. Invesco Ltd. now owns 227,019 shares of the company’s stock worth $8,352,000 after acquiring an additional 36,760 shares during the last quarter. Finally, Jump Financial LLC raised its holdings in shares of Revolution Medicines by 87.9% in the second quarter. Jump Financial LLC now owns 15,258 shares of the company’s stock worth $561,000 after acquiring an additional 7,137 shares during the last quarter. Hedge funds and other institutional investors own 94.34% of the company’s stock.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.